Nonclinical immunotoxicity evaluation is an important component of safety assessment for pharmaceuticals. One in vitro assay that can be applied in a weight of evidence assessment is the human lymphocyte activation (HuLA) assay, an antigen recall assay, similar in many respects to the in vivo T-cell-dependent antibody response (TDAR) in that cooperation of multiple immune cell types are needed to produce responses. This assay uses human cells and is more amenable than the TDAR to compound ranking and mechanistic studies.
Full text online: https://www.tandfonline.com/doi/full/10.1080/1547691X.2020.1725694
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.